BS194
Modify Date: 2024-01-08 17:37:39
BS194 structure
|
Common Name | BS194 | ||
|---|---|---|---|---|
| CAS Number | 1092443-55-4 | Molecular Weight | 385.460 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C20H27N5O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BS194BS-194 is an orally active, selective and potent CDK inhibitor. BS-194 inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50s: 3, 30, 30, 250, and 90 nM respectively). BS-194 potently inhibits cancer cells proliferation. BS-194 can be used in the research of cancers like breast cancer, colon cancer[1]. |
| Name | (2S,3S)-3-{[7-(Benzylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-5 -yl]amino}-1,2,4-butanetriol |
|---|---|
| Synonym | More Synonyms |
| Description | BS-194 is an orally active, selective and potent CDK inhibitor. BS-194 inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50s: 3, 30, 30, 250, and 90 nM respectively). BS-194 potently inhibits cancer cells proliferation. BS-194 can be used in the research of cancers like breast cancer, colon cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
CDK2:3 nM (IC50) CDK1:30 nM (IC50) CDK5:30 nM (IC50) CDK7:250 nM (IC50) CDK9:90 nM (IC50) |
| In Vitro | BS-194 (compound 4k, 72 h) inhibits various cancer cell growth, with IC50 values ranging from 100 nM to 1 μM[1]. BS-194 (10 μM, 24 h) promotes cell cycle arrest in in S and G2/M phases in HCT116 cells[1]. BS-194 (10 μM, 24 h) inhibits phosphorylation of CDK substrates, and promotes cyclin loss in HCT116 cells[1]. Cell Cycle Analysis[1] Cell Line: HCT116 Concentration: 0, 0.01, 0.1, 1, 10 μM Incubation Time: 24 h Result: Showed a significant reduction in G1, and increased in S and G2/M phases. Western Blot Analysis[1] Cell Line: HCT116 Concentration: 0, 0.1, 10, 20 μM Incubation Time: 0, 0.1, 10, 20 μM Result: Inhibited the phosphorylation of the CDK2 substrate RB (retinoblastoma) at Ser-780, Ser-795, Ser-801, Ser-807/Ser-811, and Thr-821. Inhibited levels of cyclin A, cyclin B, and cyclin D1. Inhibited phosphorylation of Thr-170 of CDK2. |
| In Vivo | BS-194 (compound 4K, intraperitoneal injection, 5 or 10 mg/kg, twice daily for 14 days) inhibits tumor growth with no apparent toxicity in MCF-7 tumor xenografts[1]. BS-194 (i.p., i.v., p.o., 10 mg/kg) is orally bioavailable, with elimination half-lives of 147 min (i.p.), 210 min (i.v.), and 178 min (p.o.) respectively[1]. BS-194 (oral gavage, 25 mg/mL) reduces rapid RB and PolII (RNA polymerase II) phosphorylation, but recovery within 24 h in nu/nu-BALB/c athymic nude mice[1]. BS-194 (oral gavage, 25 mg/kg, daily for 14 days) inhibits tumor growth in HCT116 tumor xenografts, with no significant loss in animal weights[1]. Animal Model: Nude mice bearing MCF-7 cell[1] Dosage: 5 or 10 mg/kg, twice daily for 14 days. Administration: Intraperitoneal injection Result: Inhibited tumor growth in a dose-dependent manner (30% and 40% reduction at 5 and 10 mg/kg dose, respectively). Animal Model: HCT116 tumor xenografts[1] Dosage: 25 mg/kg, daily for 14 days. Administration: Oral gavage Result: Inhibited tumor growth by 50% reduction at 25 mg/kg. Decreased levels of Rb phosphorylation at Ser807/811 and Thr821 (in resected tumors). Animal Model: Mice (pharmacokinetic assay)[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection, intravenous injection, oral administration Result: Pharmacokinetic profile of BS-194 (compound 4k). administration route dose (mg/kg) bioavail-ability (%) Cmax (min) T1/2 (min) i.p. 10 73 30 147 p.o. 10 88 15 178 administration route dose (mg/kg) T1/2 (min) Cl (mL/min/kg) Vz i.v. 10 210 5 1391 |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C20H27N5O3 |
| Molecular Weight | 385.460 |
| Exact Mass | 385.211395 |
| PSA | 114.94000 |
| LogP | 1.37 |
| Index of Refraction | 1.651 |
![tert-butyl benzyl(5-(((2S,3S)-1-((tert-butyldimethylsilyl)oxy)-3,4-dihydroxybutan-2-yl)amino)-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate structure](https://image.chemsrc.com/caspic/111/1092444-51-3.png)
| Precursor 1 | |
|---|---|
| DownStream 0 | |
| (2S,3S)-3-{[7-(Benzylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-5-yl]amino}-1,2,4-butanetriol |
| 1,2,4-Butanetriol, 3-[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-, (2S,3S)- |
| BS194 |